Abstract
The aim of this review was to summarize the recent evidences regarding the pharmacological treatment of panic disorder (PD). The authors performed a review of the literature regarding the pharmacological treatment of PD since the year 2000. The research done in the last decade brought strong evidences of effectiveness for paroxetine, venlafaxine, sertraline, fluvoxamine, citalopram, fluoxetine, clonazepam, and the relatively novel agent escitalopram. There are evidences indicating that the other new compounds inositol, duloxetine, mirtazapine, milnacipran, and nefazodone have antipanic properties and may be effective compounds in the treatment of PD. The effectiveness of reboxetine and anticonvulsants is a subject of controversy. In addition to selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines and atypical antipsychotics may be valid alternatives in the treatment of PD. Recent data indicate that augmentation strategies with aripiprazole, olanzapine, pindolol or clonazepam may be effective. D-cycloserine is a promising agent in the augmentation of cognitive behavioral therapy.
Keywords: Anti-anxiety agents, antidepressive agents, antipsychotic agents, benzodiazepines, clinical trial, cognitive therapy, comparative study, panic disorder.
CNS & Neurological Disorders - Drug Targets
Title:Current Pharmacological Interventions in Panic Disorder
Volume: 13 Issue: 6
Author(s): Rafael C. Freire, Sergio Machado, Oscar Arias-Carrion and Antonio E. Nardi
Affiliation:
Keywords: Anti-anxiety agents, antidepressive agents, antipsychotic agents, benzodiazepines, clinical trial, cognitive therapy, comparative study, panic disorder.
Abstract: The aim of this review was to summarize the recent evidences regarding the pharmacological treatment of panic disorder (PD). The authors performed a review of the literature regarding the pharmacological treatment of PD since the year 2000. The research done in the last decade brought strong evidences of effectiveness for paroxetine, venlafaxine, sertraline, fluvoxamine, citalopram, fluoxetine, clonazepam, and the relatively novel agent escitalopram. There are evidences indicating that the other new compounds inositol, duloxetine, mirtazapine, milnacipran, and nefazodone have antipanic properties and may be effective compounds in the treatment of PD. The effectiveness of reboxetine and anticonvulsants is a subject of controversy. In addition to selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines and atypical antipsychotics may be valid alternatives in the treatment of PD. Recent data indicate that augmentation strategies with aripiprazole, olanzapine, pindolol or clonazepam may be effective. D-cycloserine is a promising agent in the augmentation of cognitive behavioral therapy.
Export Options
About this article
Cite this article as:
Freire C. Rafael, Machado Sergio, Arias-Carrion Oscar and Nardi E. Antonio, Current Pharmacological Interventions in Panic Disorder, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612125028
DOI https://dx.doi.org/10.2174/1871527313666140612125028 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Role of β 2-Adrenoceptor Activation in Sepsis-Induced Renal Inflammation
Current Immunology Reviews (Discontinued) A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Graphical Abstracts
Current Diabetes Reviews Dronedarone – A New Alternative for Management of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Treatment of Periodontitis for the Prevention of Endothelial Dysfunction: A Narrative Review
Current Vascular Pharmacology MRI findings and renal function in patients on lithium therapy
Current Drug Safety Investigating the Practices of Patients and Hospitals in Treatment of Diabetes - A Survey Questionnaire for Arabic Speaking Countries
Current Diabetes Reviews Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews Investigating the Relationship the Severity of Coronary Artery Disease with Serum Levels of Vitamin D in Men after Eliminating the Effect of Diet
Current Nutrition & Food Science Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets Soluble Epoxide Hydrolase: A Novel Target for the Treatment of Hypertension
Recent Patents on Cardiovascular Drug Discovery The Role of Vitamin D in Atherosclerosis Inflammation Revisited: More a Bystander than a Player?
Current Vascular Pharmacology The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets Pharmacogenetic Study of CYP2C19 Variation and Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Atherothromboticrisk Patients in Thailand
Current Pharmacogenomics and Personalized Medicine Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence
Current Pharmaceutical Design